AXSM Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 9.32%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Corcept Therapeutics, Inc.'s return on equity of 16%.

Axsome Therapeutics, Inc. has a consensus price target of $216.09, signalling upside risk potential of 16.07%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $84.00 which suggests that it could grow by 145.33%. Given that Corcept Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.400, which suggesting that the stock is 60.011% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 39.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.33x versus 5.52x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 10.24%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Axsome Therapeutics, Inc. has a consensus price target of $216.09, signalling upside risk potential of 16.07%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.05%. Given that Axsome Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.400, which suggesting that the stock is 60.011% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.33x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 27.55%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Axsome Therapeutics, Inc. has a consensus price target of $216.09, signalling upside risk potential of 16.07%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.42 which suggests that it could grow by 2.85%. Given that Axsome Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..

Axsome Therapeutics, Inc. has a beta of 0.400, which suggesting that the stock is 60.011% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 22.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.33x versus 6.45x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of -246.76%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

Axsome Therapeutics, Inc. has a consensus price target of $216.09, signalling upside risk potential of 16.07%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 123.36%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..

Axsome Therapeutics, Inc. has a beta of 0.400, which suggesting that the stock is 60.011% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.622, suggesting its less volatile than the S&P 500 by 37.837%.

Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. Axsome Therapeutics, Inc.'s net income of -$47.2M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.33x versus 1.66x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.